RxDoctor Payments Data

John Berk, MD

Pulmonary Disease · Boston, MANPI 1407831258

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $31,772 of the $33,076 with a category attached, or 96.1%. 6 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 57.7% of the total. Reporting peaked in 2023 at $24,572 and has fallen 99.9% since, to $19 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,076in general payments, 2019–2025

Across 22 payments — averaging $1503.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$19K
  • AstraZeneca$8K
  • Akcea Therapeutics, Inc.$3K
  • Merck$2K
  • Astrazeneca UK Limited$1K
  • Pfizer$934
$5,920,312in research payments, 2019–2025

Across 290 payments — averaging $20,415 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$5.5M
  • Pfizer$305K
  • AstraZeneca$83K
  • Ionis Pharmaceuticals, Inc.$52K
  • Eidos Therapeutics, Inc.$358

What the payments were for

  • Consulting fees$31,77296%
  • Speaking & faculty fees$1781%
  • Travel & lodging$7552%
  • Food & beverage$3701%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alnylam Pharmaceuticals Inc.4$19,071
AstraZeneca(2 entities)6$7,933
Akcea Therapeutics, Inc.2$2,518
Merck7$1,620
Astrazeneca UK Limited1$1,000
Pfizer2$934

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,076 in reported general payments places this provider in the 90th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$38,334
Medicare patients
193
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AmvuttraVutrisiran Sodium28$3,115,667
VyndamaxTafamidis98$2,344,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,660
Albuterol Sulfate HfaAlbuterol Sulfate18$543
Fluticasone Propionate13$288
Azithromycin14$46
Prednisone14$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alnylam Pharmaceuticals Inc.Amvuttra$19,071$3,115,66728 claims
PfizerVyndamax$934$2,344,53898 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 482 pulmonary disease providers in Massachusetts.

Other pulmonary disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →